Lack of association between stavudine exposure and lipoatrophy, dysglycaemia, hyperlactataemia and hypertriglyceridaemia: A prospective cross sectional study

AIDS Research and Therapy

Volumn 7, Issue , 2010, Pages

  Sinxadi, Phumla Z ^a   van der Walt, Jan Stefan ^a   McIlleron, Helen M ^a   Badri, Motasim ^a   Smith, Peter J ^a   Dave, Joel A ^a   Levitt, Naomi S ^a   Maartens, Gary ^a  

^a UNIVERSITY OF CAPE TOWN   (South Africa)

Author keywords

[No Author keywords available]

Indexed keywords

GLUCOSE; LACTIC ACID; STAVUDINE; TRIACYLGLYCEROL;

ADULT; AREA UNDER THE CURVE; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; DISTRIBUTION VOLUME; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG SAFETY; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERLACTATEMIA; HYPERTRIGLYCERIDEMIA; IMPAIRED GLUCOSE TOLERANCE; LIPOATROPHY; MALE; ORAL GLUCOSE TOLERANCE TEST; PLASMA CONCENTRATION-TIME CURVE; PRIORITY JOURNAL;

EID: 77955403568     PISSN: 17426405     EISSN: None     Source Type: Journal    
DOI: 10.1186/1742-6405-7-23     Document Type: Article

References (37)

1. WHO Addendum to the 2006 WHO guidelines on antiretroviral therapy for HIV infection in adults and adolescents. (date last accessed 28 September 2008)., WHO., http://www.who.int/hiv/art/ARTadultsaddendum.pdf
2. Boulle A, Orrell C, Kaplan R, van Cutsem G, McNally M, Hilderbrand K, et al. Substitution due to antiretroviral toxicity or contraindication in the first 3 years of antiretroviral treatment in a large South African cohort. Antivir Ther 2007, 12:753-60.
3. De Wit S, Sabin CA, Weber R, Worm SW, Reiss P, Cazanave C, et al. Incidence and risk factors for new onset diabetes in HIV-infected patients. The data collection on adverse events of anti-HIV drugs (D: A: D) study. Diabetes Care 2008, 31:1224-1229. 10.2337/dc07-2013, 2746200, 18268071.
4. World Health Organization Antiretroviral therapy for HIV infection in adults and adolescents in resource-limited settings: towards universal access. 2006, Geneva: World Health Organization, World Health Organization.
5. Hill A, Ruxrungtham K, Hanvanich M, Katlama C, Wolf E, Soriano V, et al. Systematic review of clinical trials evaluating low doses of stavudine as part of antiretroviral treatment. Expert Opin Pharmacother 2007, 8:679-688. 10.1517/14656566.8.5.679, 17376022.
6. Kakuda TN. Pharmacology of nucleoside and nucleotide reverse transcriptase inhibitor -induced mitochondrial toxicity. Clinical therapeutics 2000, 22:685-708. 10.1016/S0149-2918(00)90004-3, 10929917.
7. Velsor L, Kovacevic M, Goldstein M, Leitner HM, Lewis W, Day BJ. Mitochondrial oxidative stress in human hepatoma cells exposed to stavudine. Toxicology and Applied pharmacology 2004, 199:10-19. 10.1016/j.taap.2004.03.005, 15289086.
8. Aarnoutse RE, Schapiro JM, Boucher CA, Hekster YA, Burger DM. Therapeutic Drug Monitoring. An Aid to Optimising Response to Antiretroviral Drugs?. Drugs 2003, 63:741-53. 10.2165/00003495-200363080-00002, 12662123.
9. ter Hofstede HJM, Koopmans PP, Burger DM. Stavudine plasma concentrations and lipoatrophy. Journal of Antimicrobial Chemotherapy 2008, 61:933-938. 10.1093/jac/dkn041, 18281306.
10. American Diabetes Association Diagnosis and classification of diabetes mellitus. Diabetes care 2008, 31:S55-S60. 10.2337/dc08-S055, 18165338, American Diabetes Association.
11. Grundy SM, Cleeman JI, Merz CN, Brewer HB, Clark LT, Hunninghake DB, et al. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation 2004, 110(2):227-239. 10.1161/01.CIR.0000133317.49796.0E, 15249516.
12. Carr A, Law M. HIV lipodystrophy case definition study. JAIDS 2003, 33:571-576.
13. ACTG adherence follow-up questionnaire. on the 22 December 2006., http://www.caps.ucsf.edu/tools/surveys/pdf/2098.4188.pdf
14. Van der Walt JS, Cohen K, McIlleron HM, Smith PJ, Maartens G, Karlsson MO. Effect of rifampicin-based antitubercular therapy and cotrimoxazole on the population pharmacokinetics of stavudine (d4T) in HIV-1 infected patients. PAGE 2009, 18. Abstr 1495., http://www.page-meeting.org/?abstract=1495
15. McComsey GA, Lo Re V, O'Riordan M, Walker UA, Lebrecht D, Baron E, et al. Effect of reducing the dose of stavudine on body composition bone density and markers of mitochondrial toxicity in HIV subjects- a randomised controlled study. Clin Infect Dis 2008, 46:1290-1296. 10.1086/529384, 2430521, 18444869.
16. Ait-Mohand H, Bonmarchand M, Guiguet M, Slama L, Marguet F, Behin A, et al. Viral efficacy maintained and safety parameters improved with a reduced dose of stavudine. HIV Medicine 2008, 9:738-746. 10.1111/j.1468-1293.2008.00616.x, 18651858.
17. Anderson PL, Kakuda TN, Lichtenstein KA. The cellular pharmacology of nucleoside- and nucleotide- analogue reverse-transcriptase inhibitors and its relation ship to clinical toxicities. Clin Infect Dis 2004, 38:743-753. 10.1086/381678, 14986261.
18. Fletcher CV, Kawle SP, Kakuda TN, Anderson PL, Weller D, Bushman LR, et al. Zidovudine and lamivudine triphosphate concentration-response relationships in HIV-infected persons. AIDS 2000, 14:2137-2144. 10.1097/00002030-200009290-00010, 11061655.
19. Fletcher CV, Anderson PL, Kakuda TN, Schacker TW, Henry C, Gross C, Brundage RC. Concentration-controlled compared with conventional antiretroviral therapy for HIV infection. AIDS 2002, 16:551-560. 10.1097/00002030-200203080-00006, 11872998.
20. Hoggard PG, Lloyd J, Khoo S, Barry MG, Dann L, Gibbons SE, et al. Zidovudine phosphorylation determined sequentially over 12 months in Human Immunodeficiency Virus-infected patients with or without previous exposure to antiretroviral agents. Antimicrobial Agents and Chemotherapy 2001, 45:976-980. 10.1128/AAC.35.3.976-980.2001, 90409, 11181396.
21. Moyle G, Boffito M, Fletcher C, Higgs C, Hay PE, Song IH, et al. Steady state pharmacokinetics of abacavir in plasma and intracellular carbovir triphoshate following administration of abacavir at 600 mg milligrams once daily and 300 mg twice daily in Human Immunodeficiency Virus-infected subjects. Antimicrobial Agents and Chemotherapy 2009, 53:1532-1538. 10.1128/AAC.01000-08, 2663118, 19188387.
22. Domingo P, Cabeza MC, Pruvost A, Salazar J, del Mar Guiterrez M, Mateo MG, et al. Relationship between HIV/Highly Active Antiretroviral Therapy (HAART)-Associated Lipodystrophy Syndrome and stavudine-triphosphate intracellular levels in patients with stavudine-based antiretroviral regimens. Clinical Infectious Diseases 2010, 50. DOI: 10.1086/651117, 10.1086/651117, 20192724.
23. *LHON4917G and antiretroviral therapy-associated peripheral neuropathy. The Pharmacogenomics Journal 2008, 8:71-77. 10.1038/sj.tpj.6500470, 17684475.
24. Canter JA, Robbins GK, Selph D, Clifford DB, Kallianpur AR, Shafer R, et al. ACTG 384 and New Work Concept Sheet 273 Study Teams Mitochondrial Subhaplogroups and Peripheral Neuropathy during Antiretroviral Therapy (ART) among Non-Hispanic Black Participants in AIDS Clinical Trials Group (ACTG) Study 384. CROI 2009, Montreal, Ontario, Canada, Abstract # 160, ACTG 384 and New Work Concept Sheet 273 Study Teams.
25. Hulgan T, Tebas P, Canter JA, Mulligan K, Haas DW, Dubé M, Grinspoon S, et al. Hemochromatosis gene polymorphisms mitochondrial haplogroups and peripheral lipoatrophy during antiretroviral therapy. JID 2008, 197:858-66. 10.1086/528697, 18419350.
26. Hulgan T, Haubrich R, Riddler S, Tebas P, Ritchie MD, McComsey GA, et al. Mitochondrial DNA Haplogroups and Metabolic Changes during Antiretroviral Therapy (ART) in AIDS Clinical Trials Group (ACTG) Study A5142. Antiviral Therapy 2009, 14(Suppl 2):A17.
27. Schaad H, Petty BG, Grasela DM, Christofalo B, Raymond R, Stewart M. Pharmacokinetics and safety of a single dose of stavudine (d4T) in patients with severe hepatic impairment. Antimicrobial Agents and Chemotherapy 1997, 41:2793-2796. 164213, 9420063.
28. Kumar AKH, Ramachandran G, Rajasekaran S, Padmapriyadarsini C, Nandrenan G, Subramanyam SAS, et al. Pharmacokinetics of lamivudine & stavudine in generic fixed- dose combinations in HIV-1 infected adults in India. Indian J Med Res 2009, 130:451-457. 2853745, 19942751.
29. Zerit® (stavudine). , http://packageinserts.bms.com/pi/pi_zerit.pdf
30. van Grievesen J, De Naeyer L, Mushi T, Ubarijoro S, Gashumba D, Gazille C, Zachariah R. High prevalence of lipoatrophy among patients on stavudine-containing first-line antiretroviral therapy regimens in Rwanda. Transactions of the Royal Society of Tropical Medicine and Hygiene 2007, 101:793-798. 10.1016/j.trstmh.2007.02.020, 17467756.
31. The study of Fat Redistribution And Metabolic change in HIV infection (FRAM) Fat distribution in women with HIV infection. J Acquir Immune Defic Syndr 2006, 42:562-571. 10.1097/01.qai.0000229996.75116.da, 16837863, The study of Fat Redistribution And Metabolic change in HIV infection (FRAM).
32. Podzamczer D, Ferrer E, Sanchez P, Gatell JM, Crespo M, Fisac C, et al. Less lipoatrophy and better lipid profile with abacavir as compared to stavudine. 96 week results of a randomized study. J Acquir Immune Def Syndrome 2007, 44:139-147.
33. Haubrich RH, Riddler SA, DiRienzo AG, Komarow L, Powderly WG, Klingman K, et al. AIDS Clinical Trials Group (ACTG) A5142 Metabolic outcomes in a randomised trial of nucleoside nonnucleoside and protease inhibitor sparing regimens for initial HIV treatment. AIDS 2009, 23:1108-1118. AIDS Clinical Trials Group (ACTG) A5142.
34. Carr A, Samaras K, Thorisdottir A, Kaufmann GR, Chisholm DJ, Cooper DA. Diagnosis, prediction and natural course of HIV-1 protease-inhibitor associated lipodystrophy hyperlipidaemia, and diabetes mellitus: a cohort study. Lancet 1999, 353:2093-2099. 10.1016/S0140-6736(98)08468-2, 10382692.
35. Calza L, Manfredi R, Chiodo F. Hyperlactaemia and lactic acidosis in HIV patients receiving antiretroviral therapy. Clinical Nutrition 2005, 24:5-15. 10.1016/j.clnu.2004.03.009, 15681097.
36. Patroni A, Torti C, Tomasoni L, Roldan EQ, Bertelli D, Puoti M, et al. MASTER study group Effect of Highly Active Antiretroviral Therapy (HAART) and hepatitis C co-infection on hyperlipidaemia in HIV infected patients: A retrospective longitudinal study. HIV Clin Trials 2002, 3:451-461. 10.1310/W024-QC4T-NXU0-TKYT, 12501128, MASTER study group.
37. Domingos H, da Cunha, Paniago AMM, Martins DM, Elkhoury EB, de Souza AS. Metabolic effects to the Highly Active Antiretroviral Therapy (HAART) in AIDS patients. The Brazilian Journal of Infectious Diseases 2009, 13:130-136.